[Dr.Vad]

С точки зрения антикоагулянтной терапии:

For patients with CVT, initial anticoagulation with adjusted-dose UFH or weight-based LMWH in full anticoagulant doses is reasonable, followed by vitamin K antagonists, regardless of the presence of ICH (Class IIa; Level of Evidence B). In patients with provoked CVT (associated with a transient risk factor), vitamin K antagonists may be continued for 3 to 6 months, with a target INR of 2.0 to 3.0 (Class IIb; Level of Evidence C).

Все подробности здесь: Diagnosis and Management of Cerebral Venous Thrombosis [Ссылки доступны только зарегистрированным пользователям ]